Updated:
Milestone Pharmaceuticals
Milestone Pharmaceuticals bets its pipeline on etripamil, a nasal spray for rapid cardiac rhythm control now under FDA review with a May 2025 decision...
Milestone Pharmaceuticals
Milestone Pharmaceuticals was founded in 2005 and trades on Nasdaq under the ticker MIST. Joseph Oliveto took over as CEO in 2021, inheriting a company built around one molecule: etripamil, a fast-acting calcium channel blocker delivered as a nasal spray. The firm's intellectual property originates from academic work on as-needed cardiac rhythm management, a departure from daily maintenance drugs. The company allocates nearly all its resources to the clinical development of etripamil. Its lead indication, paroxysmal supraventricular tachycardia, affects roughly 2 million Americans, and Milestone's Phase 3 RAPID trial met its primary endpoint in 2023. A second trial for atrial fibrillation with rapid ventricular rate is ongoing. Manufacturing is outsourced, and the firm has no revenue-generating products. It funds operations through periodic equity offerings convertible debt arrangements with institutional biotech investors. Post-trial data readout in 2023, Milestone cut its workforce by roughly 80% to preserve cash and filed a New Drug Application with the FDA in October 2024, with a PDUFA target action date set for May 2025. The company maintains a small footprint in Montreal, Quebec, with a US corporate presence in Charlotte, North Carolina. As of early 2025, the firm had approximately $70 million in cash and equivalents, though it disclosed going concern language in its filings, making the FDA decision an existential event. Milestone's structural differentiator is its binary event-driven risk profile. It is a single-asset public company with no diversification, no platform technology, and no partner revenue streams. Succession planning is effectively contingent on regulatory approval and potential commercialization or acquisition, making this a pure play on whether a single nasal spray can recast the standard of care for episodic cardiac rhythm disorders.
General information
Firm type
Asset Manager
Year founded
2005
AUM
Undisclosed
Location
Region
North America
Country
Canada
City
Montreal
Corporate office
Montreal, Quebec, Canada
Additional offices
Charlotte, NC, United States
Principals
Joseph Oliveto
Chief Executive Officer
David Bharucha
Chief Medical Officer
Amit Hasija
Chief Financial Officer
Sector focus
Frequently asked questions
What is the FDA status of Milestone's lead drug candidate?
Milestone submitted a New Drug Application for etripamil to the FDA in October 2024, with a Prescription Drug User Fee Act target action date of May 2025. The application is based on the positive Phase 3 RAPID trial data for treating paroxysmal supraventricular tachycardia. An approval would mark the first at-home, on-demand treatment for this condition, which currently often requires emergency room visits for adenosine administration.
How does Milestone Pharmaceuticals fund its operations without product revenue?
Milestone is a pre-revenue stage biotech that funds clinical development and operations through periodic public equity offerings and convertible note arrangements with institutional healthcare investors. The firm reported approximately $70 million in cash and equivalents as of early 2025, but its filings include a going concern warning, meaning its ability to continue as an operating entity depends heavily on the FDA outcome or raising additional capital.
What makes etripamil different from existing cardiac arrhythmia treatments?
Etripamil is formulated as a patient-administered nasal spray designed to rapidly terminate episodes of supraventricular tachycardia within minutes, without requiring an intravenous line or a hospital visit. Current standard of care often involves patients going to an emergency department to receive intravenous adenosine or verapamil. Etripamil aims to shift that treatment to an at-home, on-demand model.
What led to the significant staff reduction at Milestone in 2023?
Following the Phase 3 RAPID trial data readout in 2023, Milestone reduced its workforce by roughly 80% to conserve cash ahead of its FDA submission. The decision reflected the company's transition from a clinical trial execution phase to a regulatory filing and potential pre-commercialization phase, requiring fewer internal resources until the drug's regulatory path is resolved.
Does Milestone have any pipeline candidates beyond etripamil?
No. Milestone is a single-asset company. Nearly all corporate resources are allocated to the etripamil program for paroxysmal supraventricular tachycardia and a Phase 2-stage indication for atrial fibrillation with rapid ventricular rate. The firm has no platform technology and does not invest in early-stage discovery, making its public market value a binary outcome wager on etripamil's approval and commercialization.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: